Kenvue (NYSE:KVUE) Price Target Cut to $22.00 by Analysts at Barclays

Kenvue (NYSE:KVUE) had its price target reduced by Barclays from $23.00 to $22.00 in a research report released on Monday,Benzinga reports. They currently have an equal weight rating on the stock.

A number of other analysts have also issued reports on KVUE. Citigroup lowered their target price on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research note on Wednesday, January 15th. Redburn Atlantic started coverage on shares of Kenvue in a research note on Thursday, April 10th. They set a “neutral” rating and a $23.50 price target for the company. UBS Group dropped their price objective on Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research note on Friday, February 7th. Piper Sandler lifted their target price on Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research report on Monday, February 24th. Finally, Canaccord Genuity Group increased their price target on Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. Eight equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $24.42.

Kenvue Price Performance

Kenvue stock opened at $22.76 on Monday. Kenvue has a 12-month low of $17.67 and a 12-month high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The firm has a 50-day moving average price of $22.80 and a 200-day moving average price of $22.40. The firm has a market capitalization of $43.50 billion, a PE ratio of 42.94, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, equities research analysts forecast that Kenvue will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th will be given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.60%. Kenvue’s payout ratio is currently 154.72%.

Institutional Investors Weigh In On Kenvue

Hedge funds and other institutional investors have recently bought and sold shares of the company. Byrne Asset Management LLC increased its position in shares of Kenvue by 1.0% during the first quarter. Byrne Asset Management LLC now owns 63,467 shares of the company’s stock worth $1,522,000 after purchasing an additional 621 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in Kenvue by 2.7% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 620,052 shares of the company’s stock worth $14,869,000 after buying an additional 16,404 shares during the last quarter. Azzad Asset Management Inc. ADV increased its position in Kenvue by 0.7% during the 1st quarter. Azzad Asset Management Inc. ADV now owns 293,990 shares of the company’s stock valued at $7,050,000 after buying an additional 2,075 shares in the last quarter. Caldwell Sutter Capital Inc. raised its stake in Kenvue by 15.9% in the first quarter. Caldwell Sutter Capital Inc. now owns 28,564 shares of the company’s stock valued at $685,000 after buying an additional 3,908 shares during the last quarter. Finally, Pullen Investment Management LLC boosted its holdings in Kenvue by 22.9% in the first quarter. Pullen Investment Management LLC now owns 85,894 shares of the company’s stock worth $2,060,000 after acquiring an additional 15,987 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.